Clinical trials: Schizophrenia Spectrum
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Stress Disorders, Post-Traumatic
Optimizing Cognitive Remediation
Veterans with mental illness face challenges with community reintegration, including achieving vocational success, attaining their educational goals and going back to school, and maintaining a high quality of life.
- Conditions
- Schizophrenia, Stress Disorders, Post-Traumatic, Generalized Anxiety Disorder, Mood Disorders
- Trial name
- NCT04395157
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Psychosis
Mindfulness, Group Therapy and Psychosis; Training Decreases Anxiety and Depression
The objective of this non-randomized, within-group comparison was to evaluate the addition of mindfulness as a new technique in an outpatient group therapy program for participants diagnosed with a psychotic spectrum disorder…
- Trial name
- NCT04711460
- Testing
- Younger participants, Older participants, TAU
- Volunteers
- 116 people
- Sponsor
- University of Minnesota
Schizophrenia, Schizo Affective Disorder
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
- Trial name
- NCT03860597
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizo-affective Disorder
Effects of Metformin and Fish Oil on Treatment With Clozapine
One purpose of this study is to test whether adding metformin will limit some of the unwanted effects of clozapine, compared to not adding metformin.
- Trial name
- NCT02140788
- Testing
- Metformin, Fish Oil
- Volunteers
- 34 people
- Sponsor
- Duke University
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia
A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia
The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.
- Trial name
- NCT01606228
- Testing
- Paliperidone ER
- Volunteers
- 188 people
- Sponsor
- Janssen Pharmaceutica
Schizophrenia
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
- Trial name
- NCT03627195
- Testing
- DSP-1349M
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sumitomo Pharma America, Inc.
Smoking Cessation
Novel Smoking Cessation Drug for Schizophrenia
The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest in quitting.
- Trial name
- TRENDS (NCT02230384)
- Testing
- Active JNJ Drug
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- K.N. Roy Chengappa
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
- Trial name
- NCT01829048
- Testing
- PF-02545920
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Schizophrenia
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
- Trial name
- NAC (NCT01232790)
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Schizophrenia
Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.
- Trial name
- NCT02174523
- Testing
- 40mg lurasidone
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with…
- Trial name
- PANDORA (NCT00761189)
- Testing
- Paliperidone
- Where
- 20 sites in South Korea
- Volunteers
- 491 people
- Sponsor
- Janssen Korea, Ltd., Korea
Obese, Cigarette-smoking
Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.
- Conditions
- Obese, Cigarette-smoking, Schizophrenia
- Trial name
- NCT02736474
- Testing
- Naltrexone, Bupropion
- Volunteers
- 22 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
Comparison of E-health vs. In-person Multi-Family Group (MFG)
As specified in the VA Uniform Services Handbook, Family Psycho-Education (FPE) treatment must be available to all Veterans with schizophrenia who could benefit, and their family members.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophrenia and Related Disorders
- Trial name
- NCT02032680
- Testing
- Web-based multi-family psychoeducational treatment, In-persons Multi-Family Group Psycho-Education treatment, Treatment as usual (TAU)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
TMS Enhancement of Visual Plasticity in Schizophrenia
The major goal is to determine if Transcranial magnetic stimulation (TMS) enhances visual plasticity in schizophrenia. TMS sessions (sham/placebo and real TMS) will be conducted before two MRI scans with two weeks in-between to…
- Trial name
- NCT03220438
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University